Phase 2 Trial of HW211026 for Actinic Keratosis Initiated
A Phase 2 clinical trial has been launched to assess HW211026's efficacy and safety in adult patients with actinic keratosis.
Company
Pharmaceutical intelligence for Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.